BBNX DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Reminds Beta Bionics, Inc. Investors They Have Until November 3rd to Seek Lead Plaintiff Role with the Firm

A class action lawsuit has been filed against Beta Bionics, Inc. for making materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The company allegedly failed to implement meaningful corrective actions despite thousands of complaints. Investors who purchased shares between July 30, 2025 and February 24, 2026 have until November 3, 2026 to apply as lead plaintiff.